{"ticker": {"uuid": "70a37aec-1dfd-4b2e-8c8c-99467b4d32e7", "symbol": "INDV", "name": "Indivior PLC Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOZW9GQi0zeWYwbUstd2h5Mk9jSTdMRW5jUGZkZkVLVEYtN2NVNzFSakpWWlpwUjBLTjRXUGpERW53VnNwb21JVjFHN2dQNHRIdXFCQWtDMEdjaUwtZU8xOGU5MS1Oa1JROEtzUTRzR1diZjk2ZFRqYnhRVlZweTdHMTRYZnNnS0k1TnQ3bDlMUFE2Y29ncFh1ZEo5QkR2eXRRbzdwMHY4OUJiQm1DSFpJVTlPYXpnOVh0Ui05NlhRNUI2VTg3YnlTOFhGQV9PRWJUSzVZSVBvTktYQVpaNWljbmhIMlQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-17T10:00:27+00:00", "published_display": "17 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock trades steady as opioid treatment specialist focuses on growth after recent earnings", "summary": "Indivior's stock performance is influenced by the balance between its growing opioid use disorder treatment sales and ongoing legal settlement costs. The company's recent earnings show strong revenue growth driven by its flagship opioid use disorder therapies, with profitability ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-stock-trades-steady-as-opioid-treatment-specialist-focuses-on/69784376", "source_name": "Ad Hoc News", "published_at": "2026-07-17T04:10:11", "published_display": "17 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock holds steady as addiction-treatment strategy stays in focus", "summary": "Indivior stock reflects the company's focus on addiction therapies, particularly opioid use disorder, positioning it within long-term healthcare trends. The company's strategy involves expanding treatment options, operating within a heavily regulated environment, and facing compe", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-stock-holds-steady-as-addiction-treatment-strategy-stays-in-focus/69777513", "source_name": "Ad Hoc News", "published_at": "2026-07-16T05:40:35", "published_display": "16 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior (INDV) Q4 2025 earnings summary", "summary": "Indivior (INDV) reported record SUBLOCADE net revenue of $856M in 2025, up 13% year-over-year, contributing to total net revenue of $1.24B. Adjusted EBITDA grew 20% to $428M, with a significant margin improvement. The company also resolved a DOJ matter for $295M and authorized a ", "url": "https://quartr.com/events/indivior-indv-q4-2025_oCc93TO0", "source_name": "Quartr", "published_at": "2026-07-14T10:17:37", "published_display": "14 Jul 2026 10:17", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INDV (NASDAQ: INDV) files Form 144 reporting 18,586 shares and $764,628 value", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPVzZHZTl6SEdiRjNGUE15cnVRXzlPX1dwRUdXMFBsSDdJNzFnTXdvQlRwNU0zNGhXX0lZYkhfM09kRi16cHBnV09DT2VudmRNRlBYVFZaLV9QbTBWQjlJNDdvZHZ1Zi03dHBFdFFyaGVkbFFlSG5QSU9JMXU1V0xVaTdSeGVvMW85RVJub2ZqT3JCNFRFazBHenMzQ2dwVkFwU05ySmc1aTA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T14:02:11+00:00", "published_display": "10 Jul 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Indivior\u2019s Multi-Index Russell 2000 Defensive Inclusion (INDV) Has Changed Its Investment Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T06:38:23+00:00", "published_display": "09 Jul 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior (INDV) Morgan Stanley 23rd Annual Global Healthcare Conference Summary", "summary": "Indivior presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, focusing on its \"Action Agenda\" with SUBLOCADE as the main growth driver. The company detailed efforts in organizational simplification, cost reduction, and improving commercial execution, especial", "url": "https://quartr.com/events/indivior-plc-indv-morgan-stanley-23rd-annual-global-healthcare-conference_oCc93gDG", "source_name": "Quartr", "published_at": "2026-07-09T06:17:37", "published_display": "09 Jul 2026 06:17", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior (INDV) Q4 2024 earnings summary", "summary": "Indivior (INDV) reported a 9% increase in FY 2024 net revenue to $1,188m, driven by a 20% rise in SUBLOCADE net revenue. The company achieved a 16% increase in adjusted operating profit and expanded its SUBLOCADE patient base by 25%. For FY 2025, Indivior anticipates a total net ", "url": "https://quartr.com/events/indivior-plc-indv-q4-2024_oCc9LmUO", "source_name": "Quartr", "published_at": "2026-07-08T18:12:32", "published_display": "08 Jul 2026 18:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC outlines its addiction treatment focus as investors weigh long-term growth", "summary": "Indivior PLC is a specialty pharmaceutical company focused on addiction treatment, particularly opioid use disorder, with a business model centered on prescription medicines. The United States is a critical market for the company due to the scale of the opioid crisis, though it a", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-plc-outlines-its-addiction-treatment-focus-as-investors-weigh/69720970", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T07:34:00", "published_display": "08 Jul 2026 07:34", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC focuses on addiction therapies as investors watch long term growth", "summary": "Indivior PLC, a specialty pharmaceutical company, is concentrating on addiction treatment, particularly for opioid use disorder. Investors are closely monitoring its pipeline, global market presence, and the regulatory environment. The company's business model relies on prescript", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-plc-focuses-on-addiction-therapies-as-investors-watch-long-term/69714788", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:13:11", "published_display": "07 Jul 2026 14:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock leans on its core addiction treatment business", "summary": "Indivior's stock performance is primarily driven by its addiction treatment portfolio, particularly for opioid use disorder. The London-listed company has a strong focus on the US market and its shares are influenced by product uptake, regulatory changes, and reimbursement condit", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-stock-leans-on-its-core-addiction-treatment-business/69711251", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T07:13:11", "published_display": "07 Jul 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sublocade from Indivior - once-monthly injection reshapes US opioid treatment", "summary": "Indivior's Sublocade, a once-monthly injection of buprenorphine, is transforming opioid use disorder treatment in the US by offering a stable, long-acting option for patients. This FDA-approved medication helps reduce daily decision-making for patients and is a strategic growth p", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/sublocade-from-indivior-once-monthly-injection-reshapes-us-opioid/69702720", "source_name": "AD HOC NEWS", "published_at": "2026-07-06T07:40:46", "published_display": "06 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC updates investors on business strategy. Focus on addiction treatment portfolio", "summary": "Indivior PLC has updated investors on its long-term business strategy, emphasizing its leadership in addiction treatment, particularly for opioid use disorder. The strategy involves expanding its product portfolio, growing its global footprint, and investing in R&D, while also fo", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-plc-updates-investors-on-business-strategy-focus-on-addiction/69695876", "source_name": "AD HOC NEWS", "published_at": "2026-07-05T11:10:35", "published_display": "05 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC outlines long-term strategy as addiction treatments remain in demand", "summary": "Indivior PLC is focusing on expanding its portfolio of addiction treatments, particularly for opioid dependence, by investing in R&D for new formulations and delivery mechanisms. The company operates in a field influenced by evolving regulation and reimbursement policies, emphasi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-plc-outlines-long-term-strategy-as-addiction-treatments-remain-in/69686786", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-04T09:40:46", "published_display": "04 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock holds the focus. US listing and product model frame the setup.", "summary": "Indivior PLC maintains a clear US-market profile with its Nasdaq listing and focus on addiction treatment pharmaceuticals, specifically for opioid use disorder. The company's business model relies on specialty medicines like SUBLOCADE, driven by treatment access and prescription ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-stock-holds-the-focus-us-listing-and-product-model-frame-the/69681985", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T19:40:00", "published_display": "03 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior navigates addiction-treatment demand. Investors weigh long-term growth prospects", "summary": "Indivior PLC, a specialty pharmaceutical company, operates at the intersection of addiction science and medicine, focusing on opioid-use disorder and related mental health conditions. The article examines how investors are evaluating its growth plans, product portfolio, and regul", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-navigates-addiction-treatment-demand-investors-weigh-long-term/69678871", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T10:39:06", "published_display": "03 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior\u2019s Triple Russell 2000 Defensive Inclusion Could Be A Game Changer For Indivior Pharmaceuticals (INDV)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/indivior-triple-russell-2000-defensive-031456703.html", "source_name": "Simply Wall St.", "published_at": "2026-06-30T03:14:56+00:00", "published_display": "30 Jun 2026 03:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPQm1tTmhqRlNqV1lfa0c1T2RPd2d2bEZGT2s4elNWX0hycFFxMUM1WFpvbERLX25hQm5zQmZOX0xYSkhpa1VGWGY5TERBWkwzVzB5X1NleWxfcEZiMHM3RmpFdnV0RzlXUzdqbXVsNmNOay1feG5pQzNueVZOX1JzUFpISmZPSmVwZFZTOFJwNmc2Uk55ZUNyMjVWOGRwUlQ5czR5TlFR?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior consensus shapes expectations, shares on Nasdaq under analyst scrutiny", "summary": "Indivior's Nasdaq listing is under analyst scrutiny, with a clear consensus forming around its earnings and valuation. This analysis focuses on how forecasts, ratings, and the sector context influence the risk-reward profile for retail investors. The company, known for its bupren", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-consensus-shapes-expectations-shares-on-nasdaq-under-analyst/69646404", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-28T11:11:06", "published_display": "28 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/zacks-industry-outlook-indivior-aurinia-085900669.html", "source_name": "Zacks", "published_at": "2026-06-26T08:59:00+00:00", "published_display": "26 Jun 2026 08:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Big Pharma's Patent Cliff Driving a New M&A Wave", "summary": "The pharmaceutical industry is facing a significant \"patent cliff\" by 2032, driving a new wave of M&A activity as major pharma companies seek to acquire innovative assets to offset potential revenue losses. Indivior (INDV), specializing in buprenorphine-based addiction treatments", "url": "https://www.kavout.com/market-lens/is-big-pharma-s-patent-cliff-driving-a-new-m-a-wave", "source_name": "Kavout | AI", "published_at": "2026-06-26T05:10:09", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects", "summary": "", "url": "https://finance.yahoo.com/m/69c5b439-5f38-30fe-ad15-4dc2e8bd2451/ibd-50-stock-indivior-breaks.html", "source_name": "Investor's Business Daily", "published_at": "2026-06-25T15:24:48+00:00", "published_display": "25 Jun 2026 15:24", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reasons Why Investors Should Consider Betting on Indivior Stock", "summary": "Indivior (INDV) is positioned as a strong investment due to the commercial success of its Sublocade treatment for opioid use disorder, with management anticipating accelerated U.S. dispense-unit growth. The company also demonstrates disciplined capital allocation by focusing on h", "url": "https://www.tradingview.com/news/zacks:15bae41b6094b:0-reasons-why-investors-should-consider-betting-on-indivior-stock/", "source_name": "TradingView", "published_at": "2026-06-25T13:09:42", "published_display": "25 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock reaches all-time high at 41.09 USD", "summary": "Indivior PLC's stock has hit an all-time high of $41.09, reflecting a 197.82% increase over the past year and suggesting the shares are slightly undervalued according to InvestingPro analysis. This surge is attributed to strong financial performance, strategic initiatives, aggres", "url": "https://www.investing.com/news/company-news/indivior-stock-reaches-alltime-high-at-4109-usd-93CH-4758524", "source_name": "Investing.com", "published_at": "2026-06-24T15:40:02", "published_display": "24 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Indivior PLC For: 23 June By Investing.com", "summary": "This article simply states that Form 4 for Indivior PLC for June 23 has been published by Investing.com. It provides no further details about the Form 4 itself, but includes various financial market data and popular news headlines as context on the publishing platform.", "url": "https://ng.investing.com/news/stock-market-news/form-4-indivior-plc-for-23-june-93CH-2571072", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T23:09:42", "published_display": "23 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals (INDV) CEO vests 1.27M shares, 612K for taxes", "summary": "Indivior Pharmaceuticals' CEO, Joseph Ciaffoni, had 1,266,903 performance stock units vest on June 22, 2026, after 100% of performance conditions were met. To cover tax withholding obligations, 612,549 of these shares were withheld, resulting in Ciaffoni directly holding 790,330 ", "url": "https://www.stocktitan.net/sec-filings/INDV/form-4-indivior-pharmaceuticals-inc-insider-trading-activity-9b31e8c64d7a.html", "source_name": "Stock Titan", "published_at": "2026-06-23T21:24:36", "published_display": "23 Jun 2026 21:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior - Weekly outlook on earnings and strategy", "summary": "This article provides an outlook on Indivior's upcoming week, highlighting the absence of new market-moving headlines and focusing investor attention on the earnings calendar, legal settlements, and strategy in opioid use disorder treatments. It details how the company generates ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-weekly-outlook-on-earnings-and-strategy/69601597", "source_name": "AD HOC NEWS", "published_at": "2026-06-22T09:00:39", "published_display": "22 Jun 2026 09:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Stock - Sunday background on the addiction-treatment specialist", "summary": "This article provides a Sunday background on Indivior, a UK-based addiction-treatment specialist, focusing on its corporate history, product portfolio, and regulatory landscape. Since there's no fresh weekend news, it offers retail investors a structured overview of the company's", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-stock-sunday-background-on-the-addiction-treatment-specialist/69594312", "source_name": "AD HOC NEWS", "published_at": "2026-06-21T05:09:50", "published_display": "21 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC (INDV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Indivior PLC (INDV), focusing on its regional contributions. As of the specified data, the United States accounts for 85.03% of the company's revenue, totaling $267.00 million, while the Rest of World contributes 14.97% or $47.00 mill", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indv/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T20:40:54", "published_display": "19 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Indivior\u2019s Once?Monthly Sublocade shot is changing opioid treatment routines", "summary": "Indivior's Sublocade is a once-monthly, extended-release buprenorphine injection designed to treat opioid use disorder, offering an alternative to daily pills. This treatment aims to provide stable buprenorphine levels, reducing daily dosing burden and diversion risk, though it r", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/why-indivior-s-once-monthly-sublocade-shot-is-changing-opioid-treatment/69579959", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T07:13:49", "published_display": "19 Jun 2026 07:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC (INDV) Valuation: PE, PB & Fair Value Analysis", "summary": "Indivior PLC (INDV) currently has a valuation score of 9.73, ranking 7th out of 157 companies in the Pharmaceuticals industry. Its P/E ratio stands at 22.80, which is significantly below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indv/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T20:40:55", "published_display": "18 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Initiates Indivior at Overweight With $46 Price Target", "summary": "Barclays has initiated coverage on Indivior with an \"Overweight\" rating and a price target of $46. This follows recent news including insider share sales, positive findings from real-world evidence studies, and the company's financial performance. Indivior Pharmaceuticals is a gl", "url": "https://www.marketscreener.com/news/barclays-initiates-indivior-at-overweight-with-46-price-target-ce7f5cdddc8df024", "source_name": "marketscreener.com", "published_at": "2026-06-18T10:09:31", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock gains new Overweight at Barclays (INDV:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQaXg0NHRid1FtS3FXTHJkWS0tSllFX2RnN1l3bTJhN0tSOHp5cFR2b2d0bnRzSU9vZGZwd25YNlIxYkxzd0dKZ1haSVBDT1pzajBQcWEzVWVhM3JlWDVpWWZVck4tanpwQ2VxUDBCanZScElkSG9KZDVqMDFVSTFTZnVNcGpWZlgzaFE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOQ2FWU1ltUllCUHhIamFKUVBIUGQwQnJiUlJ3TG5TQnp5TnZGZFFvUVRyQ1NOTkQwR09BSDRfSlViTy1xd042SFNvNDE4WFZVemQ0ZFl1VGtKXzJvcTJMZ3JPTVhkam54ZHFKaHo1Y1FXWS1tZHNLTzFVazA2cklKQVNrdWMydEpDREVFQzFRQjZPNnJpX1E4dDZkSGtfaVR3aHlIakFqQ2d0WUVPUlplZzg0MUY3emdPYldQeTk4ak4wSDR4bXBRMTl3ZHZSRmc1YUM2dW10SQ?oc=5", "source_name": "Sahm", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC (INDV) Institutional Confidence", "summary": "Indivior PLC (INDV) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion increased by 64,038,000% quarter-over-quarter, reaching 102.46%. Bill Nygren (OAKMX) is the largest institutional shar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indv/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T07:41:11", "published_display": "17 Jun 2026 07:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC (INDV) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Indivior PLC (INDV) has a current financial score of 7.94, placing it 92nd out of 157 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company recently reported a 19.17% year-over-year increase in quarterly revenue to $317.00M", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indv/financial-health", "source_name": "TradingKey", "published_at": "2026-06-16T20:39:30", "published_display": "16 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC (INDV) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Indivior PLC (INDV), focusing on its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. The stock currently has a price momentum score of 9.24 and is trading between a ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indv/technical", "source_name": "TradingKey", "published_at": "2026-06-16T19:40:50", "published_display": "16 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC Stock (GB00BYZ0C031): Tuesday focus on positioning after recent volatility", "summary": "Indivior PLC stock is drawing attention on Tuesday due to its positioning in algorithmic trading frameworks and small-cap portfolios, rather than new company-specific news. Despite a quiet news day, the stock's recent price behavior, inclusion in ETFs like the Federated Hermes MD", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-plc-stock-gb00byz0c031-tuesday-focus-on-positioning-after/69554653", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T16:10:38", "published_display": "16 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPOWZnVkJSaXNXMURSZGp0ZVBrbWhNQkJWV1dmemZISzhOSFRtTzl3d0NBUmxteGRXNW5VOTUxdUlEdm9aQnpqSlEzTk5WRmh0WmZxSVhJZnc4ZVE5YUo2SXVOcnRtbWtlbENTMXNMNkMzOE5Rc0FJMGdSX2JoS3V1YTdpUmpIYmRaR244T0h5c2tEeDY3UUF6VVU0V0M2ZlJUVlJaQUR6VUlxZw?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONVptZC1YMkhXdy1SbzdGTm4tYUU3dG5JRWVUUEROaHp4ZmJSUGJydFByWWZnNFJIcTlCTHJSVDhrZnR5ZDZETFpPV0lPaExlejM0UVhSV0lzUmk1TmJqMkxYVFpLWjNYY1JOeHgwWUZqUFlZZ1FaNTJXT2NPT3JIUkVpTWNia1RrRTJoZi1uYmd5VXZ6RDktOHJNd1JweTE4Mnc3UjdB?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sale: Chief Financial Officer of $INDV Sells 36,000 Shares | INDV Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOV051VVdocGlMbnNnNmpxVlZYcTBCalU3MDA2RTk2azV6NkpXUnFRMmJVT1JsbmoteTdpaFlTWWZTLXNSbEVQUVcyekh3Y2ozSU4tWm5BeG9BSXVveDlQZzN2aEdEQXFaY3lPd2lTeXlZb2k0eWRucnFWU2JrMkR6TFRDcjZ4QUN3WVp4bDc0UTQ4Tlo2aEJ5VFlrUTdxZzgzdmc3dnRGU0E?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNMk4zZnpsVllMYTBJZWpNYlZ4U2JmZGdwNzRBSXowU3o2UUp3WkFGZ2wtQ05yN08zWWZIeUlKMGU5T3JjQzYwYk9fS3liRnQtSnJFUTJvWlFvNHpnSnRTSVVxRTZnRVdralVhaGhJZGZmUUZoYk5WakUyLXVJNDlhWGp5QVI3OEZ2MzZ2ZmRUckdRT0J2aFJHSFNROHNtekhLNHFYcGlTakZUNVFVbjVvSGxta2FvVDhCUEJ2WXctNDY4TjRoZndJOU85dHFNeWpQek56bXJiczQ2SUlRYWtDNjNQODc2QQ?oc=5", "source_name": "ChartMill", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Indivior Pharmaceuticals (INDV) Could Change Following Upgraded Outlook And $175M Buyback - Learn Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQenh6LUJ4cUszLVRFQTVrMUkzRm1aS3JjSzl6T1F1N1hkMl8wbjZraENuZHhUdFoyQm1yZVBPQUtTckwwWFptNDFDdGZBTTJzY3hPbXZwaU1zVUdOUU42SDBoRmlSQ1I1U0ttY1hhWFhnNjByeW9IOWE0QzZqcnBXbFEybDNxSnQwZ0VIVXZHaC1HV19FZDBzVkEzSGZ5NlRBQ2ZoT3Jubw?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals Inc. (INDV) Is a Great Choice for 'Trend' Investors, Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQY1VONXVyYzU4bmZZRU92dVZaNzBrdGlxQzVnYjdTY0pqTnp5UjUtNnJiVUhieURWT3JqR1pyME1kRDlTY0VaM3FDdHdtYXhsWFdKZmN0ZC1IajNTQVZ5YTVWb294U0RTSXNlTUlGajkwVDNFZ2ktaldHSngtM1RSV29BRW5tZEJaeFBmNEhYaEk1Y08tYWgxbnZESzVWdmg4WFh1Y0xEWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bears are Losing Control Over Indivior Pharmaceuticals Inc. (INDV), Here's Why It's a 'Buy' Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNWW9HdjdQZDNNeFJkMkpnOXA0WXdORFZGMlJ3dTFSUEJOeVBscWw0SWhxZXpUSGhLUm5vWkZvZ3phanNkTWdMQ3BSM0Y1VWZNT2lYWXkyUzhLTmpmUG5fWmFzYzF0SExkU1FpOHlNRFA1bUhZX1pkTzNvS3ZZNURwcEVlYllpeklEY3c0cGtCWnZWVlVYNEl6dVZGSk9DR1h1?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Strong Recent Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQZFZCQnRNQmdOOVRnSWRsMFY0MHhUS3MxWmotSldQTVJ2enYtbW96LW05TWdZZk04cFNrN2RUYlhDUXVmMzFmbG1GalNaZlVqYzNmdzUzVHd4OTJlTFZPRndKLTF1eURfbVY4OWt3b0ZWY1VoNGl0Ql94bndKdV8tdzRNOHFTVnZTRW5XNHcxajlIX29haV9zTmU1ZFFSN1lrOVppMXVQWnU2bWF1?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZ2FkMXh3WkRrQWFrdmlVNnp3M2RZUXllMHNHLWQyQkVNbGZsNW5WNGY5Q0xDRFRHTURXc1czWlIyTnp3NExrMEZKVWhiaGwzZ1NLb003SzlEcXFmMWZUOXBkU1BDekVuZDY1Y2dPZndvNUZGa1QtU1dBSVRVMUlSSk8zeDdhVFN6eTJUek56bTU1RkRJQm5qNnprYjMyLVZDYl9rNWtjaHJSbjg?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNNnN4SlpyeUNRSEVfT3pDYTgzc1NQcHl0Q2JWZHhnUjJNbUV0VHNXcFdYb0cyaEF0cXdVS0g1djJlWjJhU3pZUkxySVRKZ1ZiYzRiT1ptOS1OSU1GNFZJNVQySU1Ea0t4eldONHc4RlVncmZZV2RXX2tubmVXNHBrYVUyMzR5bWJsTmhveDZwZDdPLWJyMVkydU9CV05KVTdEOEdjWjllRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals Inc. (INDV): Billionaire Howard Marks Trims Stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNMEZrRXd4ZDFqblNScmZPRlR3b1RIRlAxREpOT3BvRVQtZ2ozc2dtVkVWclBUM3d6RUpiamNCbXU5UV9Ec0tfNElkS0pJNVlNdG1tOGRublRlWS11eWJMM2hjTHEtM0YyQ0N4RkNta2FLTFB3aUJrbDhYc2gyRXhTQkYtZFBfNEpDbDREenMxdmFBazVQQmktNmM2YW1fS01CQWoza0h3ZkZWbXIzNHY4?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals (INDV) Valuation Check After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPblE5Y2gwaGUwVGR2RDlDQ2lYenFGaVRya0J6NW9teDE1SURISVhfa1pYczFNc1ZBaklIOHJUaDEyeS1NaEdZSWtXQmhVN0Q2RmptekQ5VzB2UFVPa0RPUVhuRlhnOU4wc0h5LUFFYjV5RXdRWTZfZi1tak95RURKemFSMlQ2NnQ4NjFPa2FxdGE2VnNFN2JHcDFEVTFBVmc3UkRpR3hzSU1hYkQ3d1k4?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INDV Stock Price and Chart \u2014 NASDAQ:INDV", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE4yeWFJN3RZS0VhcTBsMV92eFppODhlZWs4X0NQSFQxVDZZU2VHSzlFVFotbEpKLUR6Y2w3dFdnVUtTemRteU9MeFNhYl9IYW54R1NJRWIzenU3R1pR?oc=5", "source_name": "TradingView", "published_at": "2025-09-26T07:00:00+00:00", "published_display": "26 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOZW9GQi0zeWYwbUstd2h5Mk9jSTdMRW5jUGZkZkVLVEYtN2NVNzFSakpWWlpwUjBLTjRXUGpERW53VnNwb21JVjFHN2dQNHRIdXFCQWtDMEdjaUwtZU8xOGU5MS1Oa1JROEtzUTRzR1diZjk2ZFRqYnhRVlZweTdHMTRYZnNnS0k1TnQ3bDlMUFE2Y29ncFh1ZEo5QkR2eXRRbzdwMHY4OUJiQm1DSFpJVTlPYXpnOVh0Ui05NlhRNUI2VTg3YnlTOFhGQV9PRWJUSzVZSVBvTktYQVpaNWljbmhIMlQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-17T10:00:27+00:00", "published_display": "17 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock trades steady as opioid treatment specialist focuses on growth after recent earnings", "summary": "Indivior's stock performance is influenced by the balance between its growing opioid use disorder treatment sales and ongoing legal settlement costs. The company's recent earnings show strong revenue growth driven by its flagship opioid use disorder therapies, with profitability ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-stock-trades-steady-as-opioid-treatment-specialist-focuses-on/69784376", "source_name": "Ad Hoc News", "published_at": "2026-07-17T04:10:11", "published_display": "17 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock holds steady as addiction-treatment strategy stays in focus", "summary": "Indivior stock reflects the company's focus on addiction therapies, particularly opioid use disorder, positioning it within long-term healthcare trends. The company's strategy involves expanding treatment options, operating within a heavily regulated environment, and facing compe", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-stock-holds-steady-as-addiction-treatment-strategy-stays-in-focus/69777513", "source_name": "Ad Hoc News", "published_at": "2026-07-16T05:40:35", "published_display": "16 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior (INDV) Q4 2025 earnings summary", "summary": "Indivior (INDV) reported record SUBLOCADE net revenue of $856M in 2025, up 13% year-over-year, contributing to total net revenue of $1.24B. Adjusted EBITDA grew 20% to $428M, with a significant margin improvement. The company also resolved a DOJ matter for $295M and authorized a ", "url": "https://quartr.com/events/indivior-indv-q4-2025_oCc93TO0", "source_name": "Quartr", "published_at": "2026-07-14T10:17:37", "published_display": "14 Jul 2026 10:17", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INDV (NASDAQ: INDV) files Form 144 reporting 18,586 shares and $764,628 value", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPVzZHZTl6SEdiRjNGUE15cnVRXzlPX1dwRUdXMFBsSDdJNzFnTXdvQlRwNU0zNGhXX0lZYkhfM09kRi16cHBnV09DT2VudmRNRlBYVFZaLV9QbTBWQjlJNDdvZHZ1Zi03dHBFdFFyaGVkbFFlSG5QSU9JMXU1V0xVaTdSeGVvMW85RVJub2ZqT3JCNFRFazBHenMzQ2dwVkFwU05ySmc1aTA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T14:02:11+00:00", "published_display": "10 Jul 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Indivior\u2019s Multi-Index Russell 2000 Defensive Inclusion (INDV) Has Changed Its Investment Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T06:38:23+00:00", "published_display": "09 Jul 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior (INDV) Morgan Stanley 23rd Annual Global Healthcare Conference Summary", "summary": "Indivior presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, focusing on its \"Action Agenda\" with SUBLOCADE as the main growth driver. The company detailed efforts in organizational simplification, cost reduction, and improving commercial execution, especial", "url": "https://quartr.com/events/indivior-plc-indv-morgan-stanley-23rd-annual-global-healthcare-conference_oCc93gDG", "source_name": "Quartr", "published_at": "2026-07-09T06:17:37", "published_display": "09 Jul 2026 06:17", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior (INDV) Q4 2024 earnings summary", "summary": "Indivior (INDV) reported a 9% increase in FY 2024 net revenue to $1,188m, driven by a 20% rise in SUBLOCADE net revenue. The company achieved a 16% increase in adjusted operating profit and expanded its SUBLOCADE patient base by 25%. For FY 2025, Indivior anticipates a total net ", "url": "https://quartr.com/events/indivior-plc-indv-q4-2024_oCc9LmUO", "source_name": "Quartr", "published_at": "2026-07-08T18:12:32", "published_display": "08 Jul 2026 18:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC outlines its addiction treatment focus as investors weigh long-term growth", "summary": "Indivior PLC is a specialty pharmaceutical company focused on addiction treatment, particularly opioid use disorder, with a business model centered on prescription medicines. The United States is a critical market for the company due to the scale of the opioid crisis, though it a", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-plc-outlines-its-addiction-treatment-focus-as-investors-weigh/69720970", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T07:34:00", "published_display": "08 Jul 2026 07:34", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC focuses on addiction therapies as investors watch long term growth", "summary": "Indivior PLC, a specialty pharmaceutical company, is concentrating on addiction treatment, particularly for opioid use disorder. Investors are closely monitoring its pipeline, global market presence, and the regulatory environment. The company's business model relies on prescript", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-plc-focuses-on-addiction-therapies-as-investors-watch-long-term/69714788", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:13:11", "published_display": "07 Jul 2026 14:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock leans on its core addiction treatment business", "summary": "Indivior's stock performance is primarily driven by its addiction treatment portfolio, particularly for opioid use disorder. The London-listed company has a strong focus on the US market and its shares are influenced by product uptake, regulatory changes, and reimbursement condit", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-stock-leans-on-its-core-addiction-treatment-business/69711251", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T07:13:11", "published_display": "07 Jul 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sublocade from Indivior - once-monthly injection reshapes US opioid treatment", "summary": "Indivior's Sublocade, a once-monthly injection of buprenorphine, is transforming opioid use disorder treatment in the US by offering a stable, long-acting option for patients. This FDA-approved medication helps reduce daily decision-making for patients and is a strategic growth p", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/sublocade-from-indivior-once-monthly-injection-reshapes-us-opioid/69702720", "source_name": "AD HOC NEWS", "published_at": "2026-07-06T07:40:46", "published_display": "06 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC updates investors on business strategy. Focus on addiction treatment portfolio", "summary": "Indivior PLC has updated investors on its long-term business strategy, emphasizing its leadership in addiction treatment, particularly for opioid use disorder. The strategy involves expanding its product portfolio, growing its global footprint, and investing in R&D, while also fo", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-plc-updates-investors-on-business-strategy-focus-on-addiction/69695876", "source_name": "AD HOC NEWS", "published_at": "2026-07-05T11:10:35", "published_display": "05 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC outlines long-term strategy as addiction treatments remain in demand", "summary": "Indivior PLC is focusing on expanding its portfolio of addiction treatments, particularly for opioid dependence, by investing in R&D for new formulations and delivery mechanisms. The company operates in a field influenced by evolving regulation and reimbursement policies, emphasi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-plc-outlines-long-term-strategy-as-addiction-treatments-remain-in/69686786", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-04T09:40:46", "published_display": "04 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock holds the focus. US listing and product model frame the setup.", "summary": "Indivior PLC maintains a clear US-market profile with its Nasdaq listing and focus on addiction treatment pharmaceuticals, specifically for opioid use disorder. The company's business model relies on specialty medicines like SUBLOCADE, driven by treatment access and prescription ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-stock-holds-the-focus-us-listing-and-product-model-frame-the/69681985", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T19:40:00", "published_display": "03 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior navigates addiction-treatment demand. Investors weigh long-term growth prospects", "summary": "Indivior PLC, a specialty pharmaceutical company, operates at the intersection of addiction science and medicine, focusing on opioid-use disorder and related mental health conditions. The article examines how investors are evaluating its growth plans, product portfolio, and regul", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-navigates-addiction-treatment-demand-investors-weigh-long-term/69678871", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T10:39:06", "published_display": "03 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior\u2019s Triple Russell 2000 Defensive Inclusion Could Be A Game Changer For Indivior Pharmaceuticals (INDV)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/indivior-triple-russell-2000-defensive-031456703.html", "source_name": "Simply Wall St.", "published_at": "2026-06-30T03:14:56+00:00", "published_display": "30 Jun 2026 03:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPQm1tTmhqRlNqV1lfa0c1T2RPd2d2bEZGT2s4elNWX0hycFFxMUM1WFpvbERLX25hQm5zQmZOX0xYSkhpa1VGWGY5TERBWkwzVzB5X1NleWxfcEZiMHM3RmpFdnV0RzlXUzdqbXVsNmNOay1feG5pQzNueVZOX1JzUFpISmZPSmVwZFZTOFJwNmc2Uk55ZUNyMjVWOGRwUlQ5czR5TlFR?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior consensus shapes expectations, shares on Nasdaq under analyst scrutiny", "summary": "Indivior's Nasdaq listing is under analyst scrutiny, with a clear consensus forming around its earnings and valuation. This analysis focuses on how forecasts, ratings, and the sector context influence the risk-reward profile for retail investors. The company, known for its bupren", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-consensus-shapes-expectations-shares-on-nasdaq-under-analyst/69646404", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-28T11:11:06", "published_display": "28 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/zacks-industry-outlook-indivior-aurinia-085900669.html", "source_name": "Zacks", "published_at": "2026-06-26T08:59:00+00:00", "published_display": "26 Jun 2026 08:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Big Pharma's Patent Cliff Driving a New M&A Wave", "summary": "The pharmaceutical industry is facing a significant \"patent cliff\" by 2032, driving a new wave of M&A activity as major pharma companies seek to acquire innovative assets to offset potential revenue losses. Indivior (INDV), specializing in buprenorphine-based addiction treatments", "url": "https://www.kavout.com/market-lens/is-big-pharma-s-patent-cliff-driving-a-new-m-a-wave", "source_name": "Kavout | AI", "published_at": "2026-06-26T05:10:09", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects", "summary": "", "url": "https://finance.yahoo.com/m/69c5b439-5f38-30fe-ad15-4dc2e8bd2451/ibd-50-stock-indivior-breaks.html", "source_name": "Investor's Business Daily", "published_at": "2026-06-25T15:24:48+00:00", "published_display": "25 Jun 2026 15:24", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reasons Why Investors Should Consider Betting on Indivior Stock", "summary": "Indivior (INDV) is positioned as a strong investment due to the commercial success of its Sublocade treatment for opioid use disorder, with management anticipating accelerated U.S. dispense-unit growth. The company also demonstrates disciplined capital allocation by focusing on h", "url": "https://www.tradingview.com/news/zacks:15bae41b6094b:0-reasons-why-investors-should-consider-betting-on-indivior-stock/", "source_name": "TradingView", "published_at": "2026-06-25T13:09:42", "published_display": "25 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock reaches all-time high at 41.09 USD", "summary": "Indivior PLC's stock has hit an all-time high of $41.09, reflecting a 197.82% increase over the past year and suggesting the shares are slightly undervalued according to InvestingPro analysis. This surge is attributed to strong financial performance, strategic initiatives, aggres", "url": "https://www.investing.com/news/company-news/indivior-stock-reaches-alltime-high-at-4109-usd-93CH-4758524", "source_name": "Investing.com", "published_at": "2026-06-24T15:40:02", "published_display": "24 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Indivior PLC For: 23 June By Investing.com", "summary": "This article simply states that Form 4 for Indivior PLC for June 23 has been published by Investing.com. It provides no further details about the Form 4 itself, but includes various financial market data and popular news headlines as context on the publishing platform.", "url": "https://ng.investing.com/news/stock-market-news/form-4-indivior-plc-for-23-june-93CH-2571072", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T23:09:42", "published_display": "23 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals (INDV) CEO vests 1.27M shares, 612K for taxes", "summary": "Indivior Pharmaceuticals' CEO, Joseph Ciaffoni, had 1,266,903 performance stock units vest on June 22, 2026, after 100% of performance conditions were met. To cover tax withholding obligations, 612,549 of these shares were withheld, resulting in Ciaffoni directly holding 790,330 ", "url": "https://www.stocktitan.net/sec-filings/INDV/form-4-indivior-pharmaceuticals-inc-insider-trading-activity-9b31e8c64d7a.html", "source_name": "Stock Titan", "published_at": "2026-06-23T21:24:36", "published_display": "23 Jun 2026 21:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior - Weekly outlook on earnings and strategy", "summary": "This article provides an outlook on Indivior's upcoming week, highlighting the absence of new market-moving headlines and focusing investor attention on the earnings calendar, legal settlements, and strategy in opioid use disorder treatments. It details how the company generates ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-weekly-outlook-on-earnings-and-strategy/69601597", "source_name": "AD HOC NEWS", "published_at": "2026-06-22T09:00:39", "published_display": "22 Jun 2026 09:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Stock - Sunday background on the addiction-treatment specialist", "summary": "This article provides a Sunday background on Indivior, a UK-based addiction-treatment specialist, focusing on its corporate history, product portfolio, and regulatory landscape. Since there's no fresh weekend news, it offers retail investors a structured overview of the company's", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-stock-sunday-background-on-the-addiction-treatment-specialist/69594312", "source_name": "AD HOC NEWS", "published_at": "2026-06-21T05:09:50", "published_display": "21 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC (INDV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Indivior PLC (INDV), focusing on its regional contributions. As of the specified data, the United States accounts for 85.03% of the company's revenue, totaling $267.00 million, while the Rest of World contributes 14.97% or $47.00 mill", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indv/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T20:40:54", "published_display": "19 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Indivior\u2019s Once?Monthly Sublocade shot is changing opioid treatment routines", "summary": "Indivior's Sublocade is a once-monthly, extended-release buprenorphine injection designed to treat opioid use disorder, offering an alternative to daily pills. This treatment aims to provide stable buprenorphine levels, reducing daily dosing burden and diversion risk, though it r", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/why-indivior-s-once-monthly-sublocade-shot-is-changing-opioid-treatment/69579959", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T07:13:49", "published_display": "19 Jun 2026 07:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC (INDV) Valuation: PE, PB & Fair Value Analysis", "summary": "Indivior PLC (INDV) currently has a valuation score of 9.73, ranking 7th out of 157 companies in the Pharmaceuticals industry. Its P/E ratio stands at 22.80, which is significantly below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indv/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T20:40:55", "published_display": "18 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Initiates Indivior at Overweight With $46 Price Target", "summary": "Barclays has initiated coverage on Indivior with an \"Overweight\" rating and a price target of $46. This follows recent news including insider share sales, positive findings from real-world evidence studies, and the company's financial performance. Indivior Pharmaceuticals is a gl", "url": "https://www.marketscreener.com/news/barclays-initiates-indivior-at-overweight-with-46-price-target-ce7f5cdddc8df024", "source_name": "marketscreener.com", "published_at": "2026-06-18T10:09:31", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior stock gains new Overweight at Barclays (INDV:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQaXg0NHRid1FtS3FXTHJkWS0tSllFX2RnN1l3bTJhN0tSOHp5cFR2b2d0bnRzSU9vZGZwd25YNlIxYkxzd0dKZ1haSVBDT1pzajBQcWEzVWVhM3JlWDVpWWZVck4tanpwQ2VxUDBCanZScElkSG9KZDVqMDFVSTFTZnVNcGpWZlgzaFE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOQ2FWU1ltUllCUHhIamFKUVBIUGQwQnJiUlJ3TG5TQnp5TnZGZFFvUVRyQ1NOTkQwR09BSDRfSlViTy1xd042SFNvNDE4WFZVemQ0ZFl1VGtKXzJvcTJMZ3JPTVhkam54ZHFKaHo1Y1FXWS1tZHNLTzFVazA2cklKQVNrdWMydEpDREVFQzFRQjZPNnJpX1E4dDZkSGtfaVR3aHlIakFqQ2d0WUVPUlplZzg0MUY3emdPYldQeTk4ak4wSDR4bXBRMTl3ZHZSRmc1YUM2dW10SQ?oc=5", "source_name": "Sahm", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC (INDV) Institutional Confidence", "summary": "Indivior PLC (INDV) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion increased by 64,038,000% quarter-over-quarter, reaching 102.46%. Bill Nygren (OAKMX) is the largest institutional shar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indv/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T07:41:11", "published_display": "17 Jun 2026 07:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC (INDV) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Indivior PLC (INDV) has a current financial score of 7.94, placing it 92nd out of 157 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company recently reported a 19.17% year-over-year increase in quarterly revenue to $317.00M", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indv/financial-health", "source_name": "TradingKey", "published_at": "2026-06-16T20:39:30", "published_display": "16 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC (INDV) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Indivior PLC (INDV), focusing on its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. The stock currently has a price momentum score of 9.24 and is trading between a ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indv/technical", "source_name": "TradingKey", "published_at": "2026-06-16T19:40:50", "published_display": "16 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior PLC Stock (GB00BYZ0C031): Tuesday focus on positioning after recent volatility", "summary": "Indivior PLC stock is drawing attention on Tuesday due to its positioning in algorithmic trading frameworks and small-cap portfolios, rather than new company-specific news. Despite a quiet news day, the stock's recent price behavior, inclusion in ETFs like the Federated Hermes MD", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/indivior-plc-stock-gb00byz0c031-tuesday-focus-on-positioning-after/69554653", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T16:10:38", "published_display": "16 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPOWZnVkJSaXNXMURSZGp0ZVBrbWhNQkJWV1dmemZISzhOSFRtTzl3d0NBUmxteGRXNW5VOTUxdUlEdm9aQnpqSlEzTk5WRmh0WmZxSVhJZnc4ZVE5YUo2SXVOcnRtbWtlbENTMXNMNkMzOE5Rc0FJMGdSX2JoS3V1YTdpUmpIYmRaR244T0h5c2tEeDY3UUF6VVU0V0M2ZlJUVlJaQUR6VUlxZw?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONVptZC1YMkhXdy1SbzdGTm4tYUU3dG5JRWVUUEROaHp4ZmJSUGJydFByWWZnNFJIcTlCTHJSVDhrZnR5ZDZETFpPV0lPaExlejM0UVhSV0lzUmk1TmJqMkxYVFpLWjNYY1JOeHgwWUZqUFlZZ1FaNTJXT2NPT3JIUkVpTWNia1RrRTJoZi1uYmd5VXZ6RDktOHJNd1JweTE4Mnc3UjdB?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sale: Chief Financial Officer of $INDV Sells 36,000 Shares | INDV Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOV051VVdocGlMbnNnNmpxVlZYcTBCalU3MDA2RTk2azV6NkpXUnFRMmJVT1JsbmoteTdpaFlTWWZTLXNSbEVQUVcyekh3Y2ozSU4tWm5BeG9BSXVveDlQZzN2aEdEQXFaY3lPd2lTeXlZb2k0eWRucnFWU2JrMkR6TFRDcjZ4QUN3WVp4bDc0UTQ4Tlo2aEJ5VFlrUTdxZzgzdmc3dnRGU0E?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNMk4zZnpsVllMYTBJZWpNYlZ4U2JmZGdwNzRBSXowU3o2UUp3WkFGZ2wtQ05yN08zWWZIeUlKMGU5T3JjQzYwYk9fS3liRnQtSnJFUTJvWlFvNHpnSnRTSVVxRTZnRVdralVhaGhJZGZmUUZoYk5WakUyLXVJNDlhWGp5QVI3OEZ2MzZ2ZmRUckdRT0J2aFJHSFNROHNtekhLNHFYcGlTakZUNVFVbjVvSGxta2FvVDhCUEJ2WXctNDY4TjRoZndJOU85dHFNeWpQek56bXJiczQ2SUlRYWtDNjNQODc2QQ?oc=5", "source_name": "ChartMill", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Indivior Pharmaceuticals (INDV) Could Change Following Upgraded Outlook And $175M Buyback - Learn Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQenh6LUJ4cUszLVRFQTVrMUkzRm1aS3JjSzl6T1F1N1hkMl8wbjZraENuZHhUdFoyQm1yZVBPQUtTckwwWFptNDFDdGZBTTJzY3hPbXZwaU1zVUdOUU42SDBoRmlSQ1I1U0ttY1hhWFhnNjByeW9IOWE0QzZqcnBXbFEybDNxSnQwZ0VIVXZHaC1HV19FZDBzVkEzSGZ5NlRBQ2ZoT3Jubw?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals Inc. (INDV) Is a Great Choice for 'Trend' Investors, Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQY1VONXVyYzU4bmZZRU92dVZaNzBrdGlxQzVnYjdTY0pqTnp5UjUtNnJiVUhieURWT3JqR1pyME1kRDlTY0VaM3FDdHdtYXhsWFdKZmN0ZC1IajNTQVZ5YTVWb294U0RTSXNlTUlGajkwVDNFZ2ktaldHSngtM1RSV29BRW5tZEJaeFBmNEhYaEk1Y08tYWgxbnZESzVWdmg4WFh1Y0xEWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bears are Losing Control Over Indivior Pharmaceuticals Inc. (INDV), Here's Why It's a 'Buy' Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNWW9HdjdQZDNNeFJkMkpnOXA0WXdORFZGMlJ3dTFSUEJOeVBscWw0SWhxZXpUSGhLUm5vWkZvZ3phanNkTWdMQ3BSM0Y1VWZNT2lYWXkyUzhLTmpmUG5fWmFzYzF0SExkU1FpOHlNRFA1bUhZX1pkTzNvS3ZZNURwcEVlYllpeklEY3c0cGtCWnZWVlVYNEl6dVZGSk9DR1h1?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Strong Recent Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQZFZCQnRNQmdOOVRnSWRsMFY0MHhUS3MxWmotSldQTVJ2enYtbW96LW05TWdZZk04cFNrN2RUYlhDUXVmMzFmbG1GalNaZlVqYzNmdzUzVHd4OTJlTFZPRndKLTF1eURfbVY4OWt3b0ZWY1VoNGl0Ql94bndKdV8tdzRNOHFTVnZTRW5XNHcxajlIX29haV9zTmU1ZFFSN1lrOVppMXVQWnU2bWF1?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZ2FkMXh3WkRrQWFrdmlVNnp3M2RZUXllMHNHLWQyQkVNbGZsNW5WNGY5Q0xDRFRHTURXc1czWlIyTnp3NExrMEZKVWhiaGwzZ1NLb003SzlEcXFmMWZUOXBkU1BDekVuZDY1Y2dPZndvNUZGa1QtU1dBSVRVMUlSSk8zeDdhVFN6eTJUek56bTU1RkRJQm5qNnprYjMyLVZDYl9rNWtjaHJSbjg?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNNnN4SlpyeUNRSEVfT3pDYTgzc1NQcHl0Q2JWZHhnUjJNbUV0VHNXcFdYb0cyaEF0cXdVS0g1djJlWjJhU3pZUkxySVRKZ1ZiYzRiT1ptOS1OSU1GNFZJNVQySU1Ea0t4eldONHc4RlVncmZZV2RXX2tubmVXNHBrYVUyMzR5bWJsTmhveDZwZDdPLWJyMVkydU9CV05KVTdEOEdjWjllRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals Inc. (INDV): Billionaire Howard Marks Trims Stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNMEZrRXd4ZDFqblNScmZPRlR3b1RIRlAxREpOT3BvRVQtZ2ozc2dtVkVWclBUM3d6RUpiamNCbXU5UV9Ec0tfNElkS0pJNVlNdG1tOGRublRlWS11eWJMM2hjTHEtM0YyQ0N4RkNta2FLTFB3aUJrbDhYc2gyRXhTQkYtZFBfNEpDbDREenMxdmFBazVQQmktNmM2YW1fS01CQWoza0h3ZkZWbXIzNHY4?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indivior Pharmaceuticals (INDV) Valuation Check After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPblE5Y2gwaGUwVGR2RDlDQ2lYenFGaVRya0J6NW9teDE1SURISVhfa1pYczFNc1ZBaklIOHJUaDEyeS1NaEdZSWtXQmhVN0Q2RmptekQ5VzB2UFVPa0RPUVhuRlhnOU4wc0h5LUFFYjV5RXdRWTZfZi1tak95RURKemFSMlQ2NnQ4NjFPa2FxdGE2VnNFN2JHcDFEVTFBVmc3UkRpR3hzSU1hYkQ3d1k4?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INDV Stock Price and Chart \u2014 NASDAQ:INDV", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE4yeWFJN3RZS0VhcTBsMV92eFppODhlZWs4X0NQSFQxVDZZU2VHSzlFVFotbEpKLUR6Y2w3dFdnVUtTemRteU9MeFNhYl9IYW54R1NJRWIzenU3R1pR?oc=5", "source_name": "TradingView", "published_at": "2025-09-26T07:00:00+00:00", "published_display": "26 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 81, "total_relevant": 51, "sentiment_summary": {"positive": 30, "negative": 1, "neutral": 20, "score": 62, "total": 51, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 17.95, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 9}, {"event": "guidance", "label": "Guidance", "weight": 2.0, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 30, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 40.5, "latest_week": "2026-07-10", "one_week_move": 1.8, "four_week_move": 5.2, "twelve_week_move": 23.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.730615, "market_dynamics_buy_signal": false, "relative_strength": 12.617705, "fair_value_gap": 98.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.1676, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.8% over one week, +5.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "News confirmed by price", "tone": "positive", "classification": "confirmed_positive", "summary": "Constructive news tone is being confirmed by positive weekly price action.", "confidence": 73, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "AD HOC NEWS", "count": 9}, {"label": "TradingKey", "count": 5}, {"label": "Ad-hoc-news.de", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "ChartMill", "count": 2}, {"label": "Ad Hoc News", "count": 2}, {"label": "Stock Titan", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 9}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 3}, {"label": "Macro sensitivity", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "62/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "News confirmed by price", "tone": "positive", "text": "Constructive news tone is being confirmed by positive weekly price action."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.8% over one week, +5.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score"}], "updated_at": "2026-07-17T21:22:57.797126+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}